PHARMA CONSULTANTS R US LIMITED 11231938 false 2024-04-01 2025-03-31 2025-03-31 The principal activity of the company is Other human health activities Digita Accounts Production Advanced 6.30.9574.0 true 11231938 2024-04-01 2025-03-31 11231938 2025-03-31 11231938 core:CurrentFinancialInstruments 2025-03-31 11231938 core:CurrentFinancialInstruments core:WithinOneYear 2025-03-31 11231938 core:Non-currentFinancialInstruments core:AfterOneYear 2025-03-31 11231938 core:FurnitureFittingsToolsEquipment 2025-03-31 11231938 bus:SmallEntities 2024-04-01 2025-03-31 11231938 bus:AuditExemptWithAccountantsReport 2024-04-01 2025-03-31 11231938 bus:FilletedAccounts 2024-04-01 2025-03-31 11231938 bus:SmallCompaniesRegimeForAccounts 2024-04-01 2025-03-31 11231938 bus:RegisteredOffice 2024-04-01 2025-03-31 11231938 bus:Director1 2024-04-01 2025-03-31 11231938 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 11231938 bus:Agent1 2024-04-01 2025-03-31 11231938 core:FurnitureFittingsToolsEquipment 2024-04-01 2025-03-31 11231938 countries:AllCountries 2024-04-01 2025-03-31 11231938 2024-03-31 11231938 core:FurnitureFittingsToolsEquipment 2024-03-31 11231938 2023-04-01 2024-03-31 11231938 2024-03-31 11231938 core:CurrentFinancialInstruments 2024-03-31 11231938 core:CurrentFinancialInstruments core:WithinOneYear 2024-03-31 11231938 core:Non-currentFinancialInstruments core:AfterOneYear 2024-03-31 11231938 core:FurnitureFittingsToolsEquipment 2024-03-31 iso4217:GBP xbrli:pure

Registration number: 11231938

PHARMA CONSULTANTS R US LIMITED
Unaudited Filleted Abridged Financial Statements
for the Year Ended 31 March 2025

PHARMA CONSULTANTS R US LIMITED

Contents

Company Information | 1
Abridged Balance Sheet | 2 to 3
Notes to the Unaudited Abridged Financial Statements | 4 to 7

PHARMA CONSULTANTS R US LIMITED

Company Information

Director | Mr Krishna Surendra Patel

Registered office | Thames House, Roman Square, Sittingbourne, Kent England ME10 4BJ

Accountants | Charles Rippin & Turner Middlesex House 130 College Road Harrow Middlesex HA1 1BQ

PHARMA CONSULTANTS R US LIMITED

(Registration number: 11231938)
Abridged Balance Sheet as at 31 March 2025

| Note | 2025 £ | 2024 £
Fixed assets |  |  |
Tangible assets | 4 | 620 | 689
Current assets |  |  |
Debtors |  | 3,813 | 6,073
Cash at bank and in hand |  | 2,269 | 1,684
|  | 6,082 | 7,757
Prepayments and accrued income |  | - | 3,060
Creditors: Amounts falling due within one year |  | (1,083) | (599)
Net current assets |  | 4,999 | 10,218
Total assets less current liabilities |  | 5,619 | 10,907
Creditors: Amounts falling due after more than one year |  | (3,807) | (6,409)
Provisions for liabilities |  | - | (171)
Accruals and deferred income |  | (1,800) | (4,227)
Net assets |  | 12 | 100
Capital and reserves |  |  |
Called up share capital | 5 | 100 | 100
Retained earnings |  | (88) | -
Shareholders' funds |  | 12 | 100

For the financial year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

• | The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
• | The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

All of the company’s members have consented to the preparation of an Abridged Balance Sheet in accordance with Section 444(2A) of the Companies Act 2006.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the director on 5 February 2026

PHARMA CONSULTANTS R US LIMITED

(Registration number: 11231938)
Abridged Balance Sheet as at 31 March 2025

......................................... Mr Krishna Surendra Patel Director

PHARMA CONSULTANTS R US LIMITED

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 March 2025

1 | General information

The company is a private company limited by share capital, incorporated in England & Wales.

The address of its registered office is:
Thames House, Roman Square, Sittingbourne,
Kent
England
ME10 4BJ

These financial statements were authorised for issue by the director on 5 February 2026.

2 | Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These abridged financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These abridged financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.
The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.
The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

PHARMA CONSULTANTS R US LIMITED

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 March 2025

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.
Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.
Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.
Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.
Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Leases

Leases in which substantially all the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to profit or loss on a straight-line basis over the period of the lease.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

PHARMA CONSULTANTS R US LIMITED

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 March 2025

Dividends

Dividend distribution to the company’s shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.
Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

3 | Staff numbers

The average number of persons employed by the company (including the director) during the year, was 1 (2024 - 1).

PHARMA CONSULTANTS R US LIMITED

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 March 2025

4 | Tangible assets

| Furniture, fittings and equipment £ | Total £
Cost or valuation
At 1 April 2024 | 3,162 | 3,162
At 31 March 2025 | 3,162 | 3,162
Depreciation
At 1 April 2024 | 2,473 | 2,473
Charge for the year | 69 | 69
At 31 March 2025 | 2,542 | 2,542
Carrying amount
At 31 March 2025 | 620 | 620
At 31 March 2024 | 689 | 689

5 | Share capital

Allotted, called up and fully paid shares

| 2025 | 2024
| No. | £ | No. | £
Ordinary Share of £1 each | 100 | 100 | 100 | 100

6 | Dividends

|  | 2025 |  | 2024
|  | £ |  | £
Interim dividend of £Nil (2024 - £1,175.00) per ordinary share |  | - |  | 1,175